Lineage Cell grants director 125K stock options

Lineage Cell Therapeutics director Deborah J. Andrews received a grant of stock options covering 125,000 common shares.

Rhea-AI Filing Summary

Lineage Cell Therapeutics director Deborah J. Andrews received a grant of stock options covering 125,000 common shares. The options have an exercise price of $1.3000 per share and expire on July 1, 2036. They were awarded as a compensation-related grant rather than an open-market purchase or sale.

According to the terms, the options will vest and become exercisable on the earlier of July 1, 2027 or the date of Lineage Cell Therapeutics' next annual meeting of shareholders, provided Andrews continues to serve the company through that time. Following this grant, she holds stock options for 125,000 shares directly.

Insider Trade Summary

Grant/Award: 125,000 shares

Grant/Award 1 txn

Insider ANDREWS DEBORAH J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	125,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 125,000 contracts (Direct)

Footnotes (1)

1. F1. Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.

Key Figures

Option grant size: 125,000 shares Exercise price: $1.3000 per share Expiration date: July 1, 2036 +3 more

6 metrics

Option grant size 125,000 shares Stock Option (Right to Buy) awarded to director

Exercise price $1.3000 per share Exercise price of granted stock options

Expiration date July 1, 2036 Option term end date

Underlying shares 125,000 common shares Shares subject to the option grant

Post-transaction derivative holdings 125,000 options Total options held after the grant

Vesting condition date Earlier of July 1, 2027 or next annual meeting Vesting triggers, subject to continuous service

Key Terms

Stock Option (Right to Buy), grant/award acquisition, exercise price, annual meeting of shareholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 1.3000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of shareholders regulatory

"earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

continuous service financial

"subject in any case to the reporting person's continuous service with the issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lineage Cell Therapeutics (LCTX) director Deborah Andrews report in this Form 4?

Deborah J. Andrews reported receiving a stock option grant for 125,000 common shares of Lineage Cell Therapeutics. The options were awarded as compensation, not purchased on the open market, and give her the right to buy shares at a fixed exercise price.

How many Lineage Cell Therapeutics (LCTX) shares are covered by Deborah Andrews’ new option grant?

The new stock option grant covers 125,000 common shares of Lineage Cell Therapeutics. These options give her the right to buy that number of shares at a preset exercise price, if they vest and she chooses to exercise them later.

What is the exercise price and expiration date of Deborah Andrews’ LCTX stock options?

The options have an exercise price of $1.3000 per share and expire on July 1, 2036. This means she can buy up to 125,000 shares at $1.3000 any time after vesting and before the expiration date, subject to plan terms.

When do Deborah Andrews’ Lineage Cell Therapeutics stock options vest?

The options vest on the earlier of July 1, 2027 or the date of Lineage Cell Therapeutics’ next annual meeting of shareholders. Vesting is conditioned on her continuous service with the company through that point, according to the disclosed footnote.

Is Deborah Andrews’ Form 4 transaction in LCTX a market buy or sell?

The Form 4 shows a grant of stock options, not a market buy or sell. The transaction is classified as a grant or award acquisition, meaning she received options as compensation rather than trading existing shares on the open market.

How many Lineage Cell Therapeutics derivative securities does Deborah Andrews hold after this grant?

Following the grant, Deborah Andrews holds stock options covering 125,000 underlying common shares of Lineage Cell Therapeutics. The Form 4 shows this as her total derivative position in these options immediately after the reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ANDREWS DEBORAH J

(Last) (First) (Middle)

C/O LINEAGE CELL THERAPEUTICS

2173 SALK AVENUE, SUITE 200

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lineage Cell Therapeutics, Inc. [ LCTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.3	07/01/2026		A		125,000		(1)	07/01/2036	Common Shares	125,000	$0.00	125,000	D

Explanation of Responses:

1. Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.

	/s/ Alexandra Hernandez, as Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)